Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Early Release

  • Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure — United States, July 2016

    July 25, 2016
    CDC has updated its interim guidance for health care providers in the United States caring for pregnant women with possible Zika virus exposure, based on emerging data indicating Zika virus RNA can be detected for prolonged periods in some pregnant women. To increase the proportion of pregnant women with Zika virus infection who receive a definitive diagnosis, this guidance includes recommendations to expand real-time reverse transcription–polymerase chain reaction testing.

  • Update: Interim Guidance for Prevention of Sexual Transmission of Zika Virus — United States, July 2016

    July 25, 2016
    CDC has updated interim guidance for the prevention of sexual transmission of Zika virus. The recommendations apply to all men and women who have traveled to or reside in areas with active Zika virus transmission and their sex partners. The recommendations in this report replace those previously issued and are now updated to reduce the risk for sexual transmission of Zika virus from both men and women to their sex partners. This guidance will be updated as more information becomes available.

Current Weekly


Surveillance Summaries

  • Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance —The Gonococcal Isolate Surveillance Project,27 Sites, United States, 2014

    July 15, 2016
    Gonorrhea is the second most commonly reported notifiable disease in the United States. Prevention of sequelae and of transmission to sexual partners relies on prompt detection and effective treatment. However, treatment has been compromised by the absence of routine antimicrobial susceptibility testing in clinical care and evolution of antimicrobial resistance to the antibiotics used to treat gonorrhea. Dual therapy with ceftriaxone plus azithromycin is the only recommended gonorrhea treatment, and the potential threat of cephalosporin-resistant gonorrhea is a cause for concern. This report presents comprehensive surveillance data from the Gonococcal Isolate Surveillance Project and describes gonococcal antimicrobial susceptibility patterns in the United States during 2000–2014. Antimicrobial susceptibility surveillance data can be used to develop national treatment recommendations, set research and prevention priorities, and communicate best treatment practices to health care providers.


Recommendations and Reports

Notifiable Diseases